Santarus, Inc. (NASDAQ:SNTS)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Recs

0
Player Avatar Riccccardo4 (< 20) Submitted: 11/22/2006 3:43:28 PM : Outperform Start Price: $7.71 SNTS Score: -21.74

making great progress on their OTC version of Prilosec

Featured Broker Partners


Advertisement